This course will focus on best practices in prescribing options for the presbyope along with strategies for enhanced primary care of this patient demographic. A systematic review of best practices in visual correction options along with enhanced strategies for identifying and managing the many visual threats facing presbyopes as they age will be presented.
Almost 1200 attended our event and we received amazing feedback!
Feedback from anonymous survey:
Thank you for an interesting presentation!
Excellent entertaining lecture!
Nice to hear different perspectives on this topic.
Loved the therapeutic updates!
As a seasoned, retired, baby boomer OD it was interesting hearing how ODs now deal with presbyopic patients.
It was very helpful to hear about current and new treatment options regarding presbyopia both for glasses/Contacts as well as for IOLs.
Thank you for a great overview and refresher as well as sharing new developments in therapeutics for presbyopia correction.
Good pharmacology synopsis !
Speaker: Dr. Pamela Lowe & Dr. Marc Bloomenstein
Moderator: Dr. Jennifer Stewart
COPE ID: 96838-GO
Category: General Optometry
This event is COPE approved for 1 hour of CE credit.
Thank you to Lenz Therapeutics for exhibiting at this event.
LENZ Therapeutics is a late-stage clinical company developing innovative ophthalmic pharmaceutical products that improve vision, proudly based in San Diego.
We are focused on an eye drop to treat presbyopia and provide seamless vision for the vast majority of presbyopes.
In our pursuit of this better future for patients, we are excited to deliver an innovative solution to the eye care community, who has demonstrated their readiness.
Our novel lead program is an aceclidine based eye drop, with a unique MOA profile and best-in-class clinical data.